<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01972516</url>
  </required_header>
  <id_info>
    <org_study_id>13-375</org_study_id>
    <nct_id>NCT01972516</nct_id>
  </id_info>
  <brief_title>Tivozanib As Maintenance Therapy In GYN</brief_title>
  <official_title>A Phase II Study of Tivozanib as Maintenance Therapy, Post-Chemotherapy, in Patients With Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Comprehensive Cancer Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AVEO Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is evaluating a drug called tivozanib as a possible treatment for&#xD;
      ovarian, fallopian tube or primary peritoneal cancer.&#xD;
&#xD;
      Angiogenesis is the formation of new blood vessels. Tumors need blood vessels to grow and&#xD;
      spread. Tivozanib is an anti-angiogenesis medicine that fights cancer by cutting off a&#xD;
      tumor's blood supply so that it does not get the blood and nutrients it needs to grow.&#xD;
&#xD;
      In this research study, the Investigators are looking to see whether tivozanib works as a&#xD;
      maintenance therapy for ovarian, fallopian tube or primary peritoneal carcinoma in&#xD;
      participants who have achieved a complete response following chemotherapy. Maintenance&#xD;
      therapy is given after a disease has responded to previous treatment. It is given to help&#xD;
      prevent the spread or recurrence of the tumor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Once the participant has signed the consent form, they will be asked to undergo some&#xD;
      screening tests or procedures to find out if the participant can be in the research study.&#xD;
      Many of these tests and procedures are likely to be part of regular cancer care and may be&#xD;
      done even if it turns out that the participant do not take part in the research study. If the&#xD;
      participant has had some of these tests or procedures recently, they may or may not have to&#xD;
      be repeated.&#xD;
&#xD;
        -  A medical history, which includes questions about the participant's health, current&#xD;
           medications, and any allergies.&#xD;
&#xD;
        -  Performance status, which evaluates how the participant is able to carry on with their&#xD;
           usual activities.&#xD;
&#xD;
        -  A tumor assessment by CT (Computerized Tomography) scan or MRI (Magnetic Resonance&#xD;
           Imaging.&#xD;
&#xD;
        -  Blood tests.&#xD;
&#xD;
        -  Urine test.&#xD;
&#xD;
        -  Electrocardiogram (ECG)&#xD;
&#xD;
      If these tests show that the participant is eligible to participate in the research study,&#xD;
      the participant will begin the study treatment. If the participant does not meet the&#xD;
      eligibility criteria, the participant will not be able to participate in this research study.&#xD;
&#xD;
      Additional research procedures to be performed during this study:&#xD;
&#xD;
      - Archival tumor testing: During this study, additional tests will be performed on a sample&#xD;
      of the participant's original tumor that has been stored in the institution's tissue banks.&#xD;
      These tests will be performed on tumor tissue samples from previous biopsies or surgeries for&#xD;
      the participant's cancer.&#xD;
&#xD;
      The research done on these samples will involve looking at DNA and proteins in the&#xD;
      participant's cancer to see if researchers can learn more about the participant's type of&#xD;
      cancer and understand how tivozanib might work on their tumor. Testing of this sample will&#xD;
      not require the participant to undergo any additional research procedures.&#xD;
&#xD;
      This research sample collection is a required part of this research study.&#xD;
&#xD;
      Tissue collection / Ownership: Participation in this protocol involves providing specimen(s)&#xD;
      of participant's tissue. Please know that if the investigator leaves the institution, the&#xD;
      research and the tissue might remain at the DF/HCC or might be transferred to another&#xD;
      institution.&#xD;
&#xD;
      After the screening procedures confirm that the participant are eligible to participate in&#xD;
      the research study:&#xD;
&#xD;
      If the participant takes part in this research study, the participant will be randomized to&#xD;
      receive tivozanib by mouth or no therapy. The participant will be given a study drug diary&#xD;
      for each treatment if the participant is randomized to the tivozanib group.&#xD;
&#xD;
      Each treatment cycle lasts 28 days (4 weeks). For participants who are randomized to receive&#xD;
      tivozanib, the participant will be taking the study drug once per day for 3 weeks followed by&#xD;
      a week of rest. The diary will also include special instructions for taking the study drug.&#xD;
      The study drug will be taken once a day with plenty of water.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    due to slow accrual&#xD;
  </why_stopped>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS) Comparison</measure>
    <time_frame>2 Years</time_frame>
    <description>To compare progression-free survival of maintenance therapy with Tivozanib against standard of care in patients with ovarian, fallopian tube or primary peritoneal carcinoma who have achieved a complete response following therapy for platinum sensitive disease.&#xD;
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) Evaluation</measure>
    <time_frame>2 Years</time_frame>
    <description>To evaluate progression-free survival with no maintenance therapy in patients who have achieved a complete response following therapy for platinum sensitive disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) Evaluation</measure>
    <time_frame>2 Years</time_frame>
    <description>To evaluate the overall survival with and without maintenance therapy with Tivozanib in patients who have achieved a complete response following therapy for platinum sensitive disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity Rate Comparison</measure>
    <time_frame>2 Years</time_frame>
    <description>To compare rates of toxicity with and without maintenance therapy with Tivozanib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QOL) Evaluation</measure>
    <time_frame>2 Years</time_frame>
    <description>To evaluate the impact of treatment with Tivozanib versus placebo alone on the Quality of Life (QOL) through the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and the EORTC QLQ-Ovarian Cancer Module (EORTC QLQ-OV28) for functioning and symptoms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Primary Peritoneal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Tivozanib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tivozanib hydrochloride will be administered orally, at a dose of 1.5 mg/day, beginning on Day 1 of Cycle 1. Subjects will receive tivozanib hydrochloride once daily for 3 weeks followed by 1 week off treatment. One cycle is defined as 4 weeks. Cycles will be repeated every 4 weeks in the absence of disease progression or unacceptable toxicities.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants in the non-interventional arm will not receive study treatment, and will receive standard clinical observation and study assessments. Patients will continue to be observed in the absence of disease progression or unacceptable toxicities.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tivozanib</intervention_name>
    <arm_group_label>Tivozanib</arm_group_label>
    <other_name>Tivozanib hydrochloride</other_name>
    <other_name>AV-951</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  No evidence of disease on CT/MRI following treatment for recurrent ovarian, fallopian&#xD;
             tube, or peritoneal cancer.&#xD;
&#xD;
          -  High-grade papillary serous carcinoma of the ovary, fallopian tube or peritoneum.&#xD;
             Histological confirmation of the original primary tumor is required.&#xD;
&#xD;
          -  CA-125 within normal range.&#xD;
&#xD;
          -  Age greater than or equal to 18 years.&#xD;
&#xD;
          -  1 prior line of therapy (cytotoxic therapy only) in the recurrent setting is allowed.&#xD;
             Bevacizumab in the upfront setting allowed, however Bevacizumab or other VEGF pathway&#xD;
             targeted therapy in the recurrent setting is not allowed. Hormonal therapy does not&#xD;
             count as a prior line.&#xD;
&#xD;
          -  Recovered from effects of recent surgery, radiotherapy, and chemotherapy.&#xD;
&#xD;
          -  ECOG performance status ≤ 2&#xD;
&#xD;
        Organ and marrow function as defined below:&#xD;
&#xD;
          -  Absolute neutrophil count ≥1,250/mcL&#xD;
&#xD;
          -  Platelets ≥100,000/mcL&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 x ULN&#xD;
&#xD;
          -  AST (SGOT) / ALT (SGPT) ≤ 2.5 x institutional upper limit of normal Alkaline&#xD;
             phosphatase ≤ to 2.5 x ULN&#xD;
&#xD;
          -  Creatinine ≤ 1.5 x institutional upper limit&#xD;
&#xD;
          -  Less than or equal to 1+ proteinuria on two consecutive dipsticks taken no less than 1&#xD;
             week apart, or &lt; 1 gm protein on 24-hour urine collection or a urine&#xD;
             protein:creatinine ratio of &lt; 1.&#xD;
&#xD;
          -  INR &lt; 1.5; if on anticoagulation: INR is required to be between 2 and 3.&#xD;
&#xD;
        Patient must receive one of these three regimens for their platinum sensitive disease&#xD;
        (number of cycles should not have exceeded 8 cycles of 1 regimen in the recurrent setting):&#xD;
&#xD;
          -  Platinum (Carboplatin or Cisplatin) and Taxane (Paclitaxel or Docetaxel) Carboplatin&#xD;
             and Gemcitabine&#xD;
&#xD;
          -  Carboplatin and Liposomal Doxorubicin&#xD;
&#xD;
          -  Females not of childbearing potential or has documentation of a negative pregnancy&#xD;
             test prior to the start of the study treatment are eligible. Sexually active&#xD;
             pre-menopausal female subjects must agree to use adequate, highly effective&#xD;
             contraceptive measures, while on study and for 45 days after the last dose of last&#xD;
             study drug. Effective birth control includes (a) intrauterine device (IUD) plus one&#xD;
             barrier method; (b) oral, implantable or injectable contraceptives plus one barrier&#xD;
             method; or (c) 2 barrier methods. Effective barrier methods are male or female&#xD;
             condoms, diaphragms, and spermicides (creams or gels that contain a chemical to kill&#xD;
             sperm).&#xD;
&#xD;
          -  Able and willing to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior therapy with bevacizumab or other VEGF pathway targeted therapy in the recurrent&#xD;
             setting. Bevacizumab in the upfront setting is allowed.&#xD;
&#xD;
          -  Receiving any other study agents.&#xD;
&#xD;
          -  Subjects with treated limited stage basal cell or squamous cell carcinoma of the skin&#xD;
             or carcinoma in situ of the breast or cervix are eligible. Subjects with prior cancer&#xD;
             treated with a curative intent with no evidence of recurrent disease 5 years following&#xD;
             diagnosis and judged by the investigator to be at low risk of recurrence are eligible.&#xD;
             Subjects with any other concomitant or prior malignancies are ineligible.&#xD;
&#xD;
          -  Serious non-healing wounds or ulcers at the time of registration.&#xD;
&#xD;
          -  History of abdominal fistula or gastrointestinal perforation.&#xD;
&#xD;
          -  Active bleeding.&#xD;
&#xD;
          -  Clinically significant cardiovascular disease.&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to Tivozanib.&#xD;
&#xD;
          -  Symptomatic left ventricular dysfunction or baseline left ventricular ejection&#xD;
             fraction (LVEF) by multigated acquisition scan (MUGA) or echocardiogram (ECHO) ≤ 50 %&#xD;
             lower limit of institutional normal (LLN).&#xD;
&#xD;
          -  Uncontrolled hypertension: systolic blood pressure of &gt;140 mmHg or diastolic blood&#xD;
             pressure of &gt;90 mmHg documented on 2 consecutive measurements taken at least 24 hours&#xD;
             apart.&#xD;
&#xD;
          -  Myocardial infarction, severe angina, or unstable angina within 6 months prior to&#xD;
             administration of first dose of study drug.&#xD;
&#xD;
          -  History of serious ventricular arrhythmia (i.e., ventricular tachycardia or&#xD;
             ventricular fibrillation).&#xD;
&#xD;
          -  Cardiac arrhythmias requiring anti-arrhythmic medications (except for atrial&#xD;
             fibrillation that is well controlled with anti-arrhythmic medication).&#xD;
&#xD;
          -  Coronary or peripheral artery bypass graft within 6 months of screening.&#xD;
&#xD;
          -  History of Class III or IV congestive heart failure, as defined by the New York Heart&#xD;
             Association.&#xD;
&#xD;
          -  Central nervous system metastases.&#xD;
&#xD;
        Note: Subjects with previously treated (radiotherapy or surgery) brain metastasis that have&#xD;
        been stable without steroid treatment for at least 3 months following prior treatment may&#xD;
        be enrolled.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susana Campos, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>October 24, 2013</study_first_submitted>
  <study_first_submitted_qc>October 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2013</study_first_posted>
  <results_first_submitted>June 13, 2016</results_first_submitted>
  <results_first_submitted_qc>August 10, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 24, 2016</results_first_posted>
  <last_update_submitted>May 4, 2017</last_update_submitted>
  <last_update_submitted_qc>May 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Susana M. Campos, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Platinum-Sensitive</keyword>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Fallopian Tube Cancer</keyword>
  <keyword>Primary Peritoneal Cancer</keyword>
  <keyword>High-grade Serous</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tivozanib</title>
          <description>Tivozanib hydrochloride will be administered orally, at a dose of 1.5 mg/day, beginning on Day 1 of Cycle 1. Subjects will receive tivozanib hydrochloride once daily for 3 weeks followed by 1 week off treatment. One cycle is defined as 4 weeks. Cycles will be repeated every 4 weeks in the absence of disease progression or unacceptable toxicities.</description>
        </group>
        <group group_id="P2">
          <title>Standard Care</title>
          <description>Participants in the non-interventional arm will not receive study treatment, and will receive standard clinical observation and study assessments. Patients will continue to be observed in the absence of disease progression or unacceptable toxicities.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tivozanib</title>
          <description>Tivozanib hydrochloride will be administered orally, at a dose of 1.5 mg/day, beginning on Day 1 of Cycle 1. Subjects will receive tivozanib hydrochloride once daily for 3 weeks followed by 1 week off treatment. One cycle is defined as 4 weeks. Cycles will be repeated every 4 weeks in the absence of disease progression or unacceptable toxicities.</description>
        </group>
        <group group_id="B2">
          <title>Standard Care</title>
          <description>Participants in the non-interventional arm will not receive study treatment, and will receive standard clinical observation and study assessments. Patients will continue to be observed in the absence of disease progression or unacceptable toxicities.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-Free Survival (PFS) Comparison</title>
        <description>To compare progression-free survival of maintenance therapy with Tivozanib against standard of care in patients with ovarian, fallopian tube or primary peritoneal carcinoma who have achieved a complete response following therapy for platinum sensitive disease.&#xD;
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1)</description>
        <time_frame>2 Years</time_frame>
        <population>Reporting the number of cycles each patient completed. Each cycle = 4 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Tivozanib</title>
            <description>Tivozanib hydrochloride will be administered orally, at a dose of 1.5 mg/day, beginning on Day 1 of Cycle 1. Subjects will receive tivozanib hydrochloride once daily for 3 weeks followed by 1 week off treatment. One cycle is defined as 4 weeks. Cycles will be repeated every 4 weeks in the absence of disease progression or unacceptable toxicities.</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Participants in the non-interventional arm will not receive study treatment, and will receive standard clinical observation and study assessments. Patients will continue to be observed in the absence of disease progression or unacceptable toxicities.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival (PFS) Comparison</title>
          <description>To compare progression-free survival of maintenance therapy with Tivozanib against standard of care in patients with ovarian, fallopian tube or primary peritoneal carcinoma who have achieved a complete response following therapy for platinum sensitive disease.&#xD;
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1)</description>
          <population>Reporting the number of cycles each patient completed. Each cycle = 4 weeks.</population>
          <units>Cycles</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patient 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-Free Survival (PFS) Evaluation</title>
        <description>To evaluate progression-free survival with no maintenance therapy in patients who have achieved a complete response following therapy for platinum sensitive disease.</description>
        <time_frame>2 Years</time_frame>
        <population>Outcome measure not analyzed due to low accrual and subsequent termination of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Tivozanib</title>
            <description>Tivozanib hydrochloride will be administered orally, at a dose of 1.5 mg/day, beginning on Day 1 of Cycle 1. Subjects will receive tivozanib hydrochloride once daily for 3 weeks followed by 1 week off treatment. One cycle is defined as 4 weeks. Cycles will be repeated every 4 weeks in the absence of disease progression or unacceptable toxicities.</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Participants in the non-interventional arm will not receive study treatment, and will receive standard clinical observation and study assessments. Patients will continue to be observed in the absence of disease progression or unacceptable toxicities.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival (PFS) Evaluation</title>
          <description>To evaluate progression-free survival with no maintenance therapy in patients who have achieved a complete response following therapy for platinum sensitive disease.</description>
          <population>Outcome measure not analyzed due to low accrual and subsequent termination of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) Evaluation</title>
        <description>To evaluate the overall survival with and without maintenance therapy with Tivozanib in patients who have achieved a complete response following therapy for platinum sensitive disease.</description>
        <time_frame>2 Years</time_frame>
        <population>Outcome measure not analyzed due to low accrual and subsequent termination of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Tivozanib</title>
            <description>Tivozanib hydrochloride will be administered orally, at a dose of 1.5 mg/day, beginning on Day 1 of Cycle 1. Subjects will receive tivozanib hydrochloride once daily for 3 weeks followed by 1 week off treatment. One cycle is defined as 4 weeks. Cycles will be repeated every 4 weeks in the absence of disease progression or unacceptable toxicities.</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Participants in the non-interventional arm will not receive study treatment, and will receive standard clinical observation and study assessments. Patients will continue to be observed in the absence of disease progression or unacceptable toxicities.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) Evaluation</title>
          <description>To evaluate the overall survival with and without maintenance therapy with Tivozanib in patients who have achieved a complete response following therapy for platinum sensitive disease.</description>
          <population>Outcome measure not analyzed due to low accrual and subsequent termination of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity Rate Comparison</title>
        <description>To compare rates of toxicity with and without maintenance therapy with Tivozanib.</description>
        <time_frame>2 Years</time_frame>
        <population>Outcome measure not analyzed due to low accrual and subsequent termination of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Tivozanib</title>
            <description>Tivozanib hydrochloride will be administered orally, at a dose of 1.5 mg/day, beginning on Day 1 of Cycle 1. Subjects will receive tivozanib hydrochloride once daily for 3 weeks followed by 1 week off treatment. One cycle is defined as 4 weeks. Cycles will be repeated every 4 weeks in the absence of disease progression or unacceptable toxicities.</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Participants in the non-interventional arm will not receive study treatment, and will receive standard clinical observation and study assessments. Patients will continue to be observed in the absence of disease progression or unacceptable toxicities.</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicity Rate Comparison</title>
          <description>To compare rates of toxicity with and without maintenance therapy with Tivozanib.</description>
          <population>Outcome measure not analyzed due to low accrual and subsequent termination of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life (QOL) Evaluation</title>
        <description>To evaluate the impact of treatment with Tivozanib versus placebo alone on the Quality of Life (QOL) through the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and the EORTC QLQ-Ovarian Cancer Module (EORTC QLQ-OV28) for functioning and symptoms.</description>
        <time_frame>2 Years</time_frame>
        <population>Outcome measure not analyzed due to low accrual and subsequent termination of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Tivozanib</title>
            <description>Tivozanib hydrochloride will be administered orally, at a dose of 1.5 mg/day, beginning on Day 1 of Cycle 1. Subjects will receive tivozanib hydrochloride once daily for 3 weeks followed by 1 week off treatment. One cycle is defined as 4 weeks. Cycles will be repeated every 4 weeks in the absence of disease progression or unacceptable toxicities.</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Participants in the non-interventional arm will not receive study treatment, and will receive standard clinical observation and study assessments. Patients will continue to be observed in the absence of disease progression or unacceptable toxicities.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life (QOL) Evaluation</title>
          <description>To evaluate the impact of treatment with Tivozanib versus placebo alone on the Quality of Life (QOL) through the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and the EORTC QLQ-Ovarian Cancer Module (EORTC QLQ-OV28) for functioning and symptoms.</description>
          <population>Outcome measure not analyzed due to low accrual and subsequent termination of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected from the time of first treatment to 30 days after the last treatment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tivozanib</title>
          <description>Tivozanib hydrochloride will be administered orally, at a dose of 1.5 mg/day, beginning on Day 1 of Cycle 1. Subjects will receive tivozanib hydrochloride once daily for 3 weeks followed by 1 week off treatment. One cycle is defined as 4 weeks. Cycles will be repeated every 4 weeks in the absence of disease progression or unacceptable toxicities.</description>
        </group>
        <group group_id="E2">
          <title>Standard Care</title>
          <description>Participants in the non-interventional arm will not receive study treatment, and will receive standard clinical observation and study assessments. Patients will continue to be observed in the absence of disease progression or unacceptable toxicities.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Athralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain - cardiac</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Athralgia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Vaginal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash maculopapular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Rash acneiform</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Terminated early due to low accrual.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Susana Campos, MD</name_or_title>
      <organization>Dana-Farber Cancer Institute</organization>
      <phone>617-632-5269</phone>
      <email>susana_campos@dfci.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

